Drugs / bone marrow-derived MSC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03166189 | Dec 2017 → Mar 2019 | Asherman syndrome, female infertility of uterine origin | D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | bone marrow-derived MSC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03166189 ↗ |
| Modality | Cell therapy | “autologous bone marrow-derived mesenchymal stem cells (MSC)” NCT03166189 ↗ |
| Route | Other | “will be transplanted to endometrial cavity” NCT03166189 ↗ |